The U.S. Health Resources and Services Administration (HRSA) yesterday announced 340B program enrollment flexibilities in New Mexico due to the declaration of a public health emergency in the state.
Category: Regulatory
Drug manufacturer Mallinckrodt’s SpecGx generic pharmaceutical subsidiary is providing refunds for 340B overcharges on 22 NDCs for purchases from Q3 2019 through Q2 2020.
Please Login or Become a Paid Subscriber to View this
Drug manufacturers Amgen and GlaxoSmithKline have announced refunds for 340B overcharges.
Please Login or Become a Paid Subscriber to View this Content
If you are
Providers and their allies praise the 340B ceiling price secure website, but it has limitations and can be made even better, 340B Report Publisher and CEO Ted Slafsky says in his latest blog post for Omnicell.
…
Breaking News
HRSA Sends Merck 340B Contract Pharmacy Cease and Desist Letter, Agency’s First in Seven Months
The federal government told drug manufacturer Merck today its conditions on 340B pricing when hospitals and health centers use contract pharmacies are illegal and must stop, or the company could face penalties of up to $6,323 per each
…
Pharmacy benefit managers (PBMs) should be stopped from usurping 340B drug discounts from HIV/AIDS clinics and other safety-net providers, Ryan White Clinics for 340B Access (RWC-340B) told the U.S. Federal Trade Commission (FTC) last week.
At least 48 hospitals lost their eligibility for 340B drug discounts for reasons related to the COVID-19 pandemic and are seeking reinstatement to the 340B program, HRSA says.
Please Login or Become a Paid
Today is the last day for hospitals that have lost their 340B eligibility due to the COVID-19 public health emergency to file paperwork to be reinstated to the drug discount program.
Please Login or Become a
U.S. Health and Human Services Secretary Xavier Becerra has extended the COVID-19 public health emergency for another 90 days, through July 15. It was due to end on Saturday, April 16.
Please Login or Become a
Astellas Pharma is issuing 340B covered entities refunds for overcharges on three NDCs for its prostate cancer treatment Xtandi and on four NDCs for its overactive bladder medication Myrbetriq for the period from Q3 2020 through Q2 2021.
…